CJC-1295 without DAC

Description

For Research Use Only. This product is supplied exclusively for laboratory research and is not intended for human or veterinary use.

CJC-1295 without DAC / Modified GRF(1-29)

CJC-1295 without DAC is the research-market name commonly used for the tetrasubstituted 29-amino-acid GHRH analogue modified GRF(1-29). ZENTRA supplies it as high-purity lyophilised research material in 5mg and 10mg formats.

Naming matters: modified GRF(1-29) lacks the albumin-binding drug-affinity-complex modification present in CJC-1295 with DAC. The two compounds therefore have different structures and should not share the same molecular mass or be treated as analytically interchangeable.

Technical Specifications

Independent Batch Testing

Every current ZENTRA CJC-1295 without DAC batch is independently tested and records an HPLC purity result above 99%. The batch number on the product label can be checked against the corresponding third-party report in our Batch Verification and COA Centre. Researchers should consult the individual report for the exact analytical methods, result and testing date for their supplied batch.

Modified GRF(1-29) Research Context

The tetrasubstituted GRF(1-29) core was developed to retain GHRH-receptor activity while improving resistance to rapid enzymatic degradation of native GRF fragments. The 2005 CJC development paper describes this modified core and the additional albumin-binding chemistry used to create the DAC version.

Direct published pharmacology for the no-DAC material is substantially thinner than the literature for CJC-1295 with DAC. Human findings from long-acting CJC-1295 studies should not be copied onto this page as if they tested modified GRF(1-29) without DAC.

Storage and Handling

For long-term storage, keep unopened lyophilised material at approximately -20°C. For short-term laboratory storage, maintain at 2-8°C. Protect the vial from light, moisture and repeated temperature changes. Use appropriate laboratory handling procedures and consult your institutional protocol before preparing research solutions.

CJC-1295 without DAC Research FAQs

What is CJC-1295 without DAC?

It is a common market name for modified GRF(1-29), a 29-amino-acid tetrasubstituted GHRH analogue.

How does it differ from CJC-1295 with DAC?

The no-DAC material lacks the maleimide-containing albumin-binding modification and the additional lysine used in the full DAC structure.

Which sizes are available?

This product is available as 5mg and 10mg of lyophilised research material. The 5mg option may be unavailable when its variation is out of stock.

Why is the evidence section cautious?

Most direct CJC-1295 pharmacokinetic studies used the long-acting DAC compound. Applying those results to modified GRF(1-29) without DAC would be scientifically misleading.

How is purity verified?

Every current batch is independently HPLC tested above 99% purity with online batch-level COA verification.

Is this product intended for human or veterinary use?

No. It is supplied strictly for laboratory research and analytical purposes.

Selected Primary Research

1. Development of tetrasubstituted hGRF(1-29) analogues and the DAC CJC-1295 structure.
2. Analytical identification of GHRH analogues including CJC-1295 without DAC.

Research Resources

• CJC-1295 with DAC
• Ipamorelin Research Peptide
• Batch Verification and COAs
• Research Peptide Storage Guide
• Lyophilised Research Material Preparation Guide
• Browse All Research Peptides

For research use only. Not for human or veterinary use.

Read our research guide comparing CJC-1295 with DAC and without DAC.